Funding available through this RFA supports company formation, as well as early research and development of novel oncology therapeutics, devices, treatment-oriented information technology products, diagnostics, or tools. The objective of the SEED Award program is to start with an interesting technology and to progress it toward a commercially viable business opportunity, i.e., make it more attractive to private funding agents. Typically, applicants have completed the following activities:

Identified a novel therapeutic, diagnostic technology, or clinical tool and shown a biological effect
Conducted preliminary safety and toxicology testing (in the case of therapeutic agents)
Shown the product can be manufactured at small scale or as a prototype
Assessed the business opportunity and organized a business plan that begins to address key issues (clinical utility, target market, financial plan, IP strategy, technical challenges, etc.) and lays out a preliminary development plan (formulation, toxicology, scale up, IND-enabling studies, phase 1 clinical trials, regulatory pathway, etc.).
Established a company